Cargando…
A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514143/ https://www.ncbi.nlm.nih.gov/pubmed/28717204 http://dx.doi.org/10.1038/s41598-017-05898-6 |
_version_ | 1783250789361254400 |
---|---|
author | Zhao, Ya-Nan Xu, Xiaoyu Wen, Na Song, Rui Meng, Qingbin Guan, Ying Cheng, Siqi Cao, Danni Dong, Yansheng Qie, Jiankun Liu, Keliang Zhang, Yongjun |
author_facet | Zhao, Ya-Nan Xu, Xiaoyu Wen, Na Song, Rui Meng, Qingbin Guan, Ying Cheng, Siqi Cao, Danni Dong, Yansheng Qie, Jiankun Liu, Keliang Zhang, Yongjun |
author_sort | Zhao, Ya-Nan |
collection | PubMed |
description | Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant, and thus maximize their therapeutic efficacy and minimize their toxic effect. Here using PEGylated salmon calcitonin (PEG-sCT)/tannic acid (TA) film as an example, we demonstrated that hydrogen-bonded layer-by-layer films of a PEGylated peptide and a polyphenol could be a platform for zero-order peptide release. The films were fabricated under mild conditions. The second component, TA, is a natural product and presents potential therapeutic activities itself. Unlike common carriers, the new carrier releases the peptide via gradual disintegration of the film because of its dynamic nature. The release of PEG-sCT follows a perfect zero-order kinetics without initial burst release. In addition the release rate could be tuned via external stimuli, such as pH and temperature. When implanted in rats, the films could remain the plasma level of PEG-sCT constant over an extended period. Accordingly, the serum calcium level was reduced and maintained constant over the same period, suggesting an improved therapeutic efficacy of the released drug. |
format | Online Article Text |
id | pubmed-5514143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55141432017-07-19 A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics Zhao, Ya-Nan Xu, Xiaoyu Wen, Na Song, Rui Meng, Qingbin Guan, Ying Cheng, Siqi Cao, Danni Dong, Yansheng Qie, Jiankun Liu, Keliang Zhang, Yongjun Sci Rep Article Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant, and thus maximize their therapeutic efficacy and minimize their toxic effect. Here using PEGylated salmon calcitonin (PEG-sCT)/tannic acid (TA) film as an example, we demonstrated that hydrogen-bonded layer-by-layer films of a PEGylated peptide and a polyphenol could be a platform for zero-order peptide release. The films were fabricated under mild conditions. The second component, TA, is a natural product and presents potential therapeutic activities itself. Unlike common carriers, the new carrier releases the peptide via gradual disintegration of the film because of its dynamic nature. The release of PEG-sCT follows a perfect zero-order kinetics without initial burst release. In addition the release rate could be tuned via external stimuli, such as pH and temperature. When implanted in rats, the films could remain the plasma level of PEG-sCT constant over an extended period. Accordingly, the serum calcium level was reduced and maintained constant over the same period, suggesting an improved therapeutic efficacy of the released drug. Nature Publishing Group UK 2017-07-17 /pmc/articles/PMC5514143/ /pubmed/28717204 http://dx.doi.org/10.1038/s41598-017-05898-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Zhao, Ya-Nan Xu, Xiaoyu Wen, Na Song, Rui Meng, Qingbin Guan, Ying Cheng, Siqi Cao, Danni Dong, Yansheng Qie, Jiankun Liu, Keliang Zhang, Yongjun A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title | A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title_full | A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title_fullStr | A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title_full_unstemmed | A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title_short | A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics |
title_sort | drug carrier for sustained zero-order release of peptide therapeutics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514143/ https://www.ncbi.nlm.nih.gov/pubmed/28717204 http://dx.doi.org/10.1038/s41598-017-05898-6 |
work_keys_str_mv | AT zhaoyanan adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT xuxiaoyu adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT wenna adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT songrui adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT mengqingbin adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT guanying adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT chengsiqi adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT caodanni adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT dongyansheng adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT qiejiankun adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT liukeliang adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT zhangyongjun adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT zhaoyanan drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT xuxiaoyu drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT wenna drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT songrui drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT mengqingbin drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT guanying drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT chengsiqi drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT caodanni drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT dongyansheng drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT qiejiankun drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT liukeliang drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics AT zhangyongjun drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics |